GRAIL Inc. lost $2.2 billion in market value after its NHS-Galleri trial failed, triggering a securities class action lawsuit for investors who bought shares between May 13, 2025 and Feb. 19, 2026.
Back
GRAIL loses $2.2B in market value as class action follows trial failure
GRAIL Inc. lost $2.2 billion in market value on Feb. 20 after its NHS-Galleri trial failed to demonstrate a reduction in late-stage cancers, triggering a securities class action lawsuit.
"The defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and concealing material adverse facts concerning the true state of GRAIL's NHS-Galleri trial," the complaint alleges. The lawsuit, filed by Rosen Law Firm, seeks to represent investors who purchased GRAIL common stock between May 13, 2025 and Feb. 19, 2026.
The trial's three-year follow-up period was insufficient to show whether the primary endpoint — a reduction in Stage III-IV cancers — was achievable, according to the complaint. Defendants repeatedly refused to provide detailed topline results or other data from the NHS-Galleri study, potentially concealing known trendlines that suggested either a longer timeline would be necessary or that the probability of achieving the statistical reduction had diminished. When the true details emerged, shares collapsed, wiping out $2.2 billion of market capitalization.
GRAIL, a spinout from Illumina Inc., went public in 2024 with the promise of a blood test capable of detecting multiple cancers at early stages. The NHS-Galleri trial, conducted with the UK's National Health Service, was the centerpiece of that investment thesis. The failure raises fundamental questions about the company's core technology and its ability to commercialize the Galleri test at scale. GRAIL had previously reported positive results from the first screening round, but the full data revealed the trial design was insufficient to prove the primary endpoint within the specified timeframe.
The lead plaintiff deadline is Aug. 4, 2026. Investors who wish to serve as lead plaintiff must move the court by that date. The case highlights the binary risk inherent in clinical-stage diagnostics companies, where a single trial readout can determine the trajectory of the entire enterprise. GRAIL's next catalyst will be any further data disclosures from the NHS-Galleri extended follow-up period or potential strategic alternatives the board may consider.
This article is for informational purposes only and does not constitute investment advice.
[1] GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS[2] ROSEN, NATIONAL TRIAL LAWYERS, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GRAL - TMX Newsfile[3] ROSEN, A TOP RANKED LAW FIRM, Encourages GRAIL, Inc. - GlobeNewswire[4] GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit[5] ROSEN, A LEADING LAW FIRM, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important ...
